98%
921
2 minutes
20
Context: Increasing evidences from experimental and human studies suggest that the activity of the growth hormone (GH/insulin-like growth factor-I) axis may contribute to the age-related cognitive decline and poor cognition in late life.
Objective: The aim of the present study was to evaluate the relationship of total serum free IGF-I and its binding protein-3 with cognitive performance in older persons aged 80 years or older.
Design: Data are from baseline evaluation of the ilSIRENTE study (n=353). Cognitive performance was evaluated using five items enclosed in the Minimum Data Set for Home Care assessment form: short-term memory, procedural memory, cognitive skills in daily decision making, verbal expression, comprehension. Free insulin-like growth factor-I (free IGF-I) and IGF-binding protein-3 (IGFBP-3) in blood were measured. Analysis of covariance (ANCOVA) was used to examine the relationship between cognitive impairment and the serum free IGF-I and IGFBP-3 concentrations, after adjustment for potential confounding variables.
Results: After adjustment for potential confounders, which included age, gender, education, cerebrovascular disease, ischemic heart disease, congestive heart failure, hypertension, diabetes, depression, Parkinson diseases, thyroid diseases, smoking status, alcohol abuse, body mass index, and number of medications, individuals with verbal expression problems (n=20) and individuals with comprehension problems (n=24) had a significantly lower serum levels of readily dissociable IGF-I than participants without cognitive impairments. The serum IGFBP-3 presented the same behavior of free IGF-I.
Conclusion: The present study suggests that among old-old subjects living in the community lower levels of total serum free IGF-I and IGFBP-3 are associated with impairment of cognitive performance. This finding suggests that the GH/IGF-I axis may play an important role in the age-related decline of cognitive performance.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ghir.2006.11.001 | DOI Listing |
Zhonghua Nan Ke Xue
August 2024
Department of Andrology, Zhengzhou University First Hospital, Zhengzhou, Henan 450000, China.
Objective: To analyze the factors for low libido in male patients with sexual dysfunction and provide some evidence for the clinical diagnosis and treatment of the condition.
Methods: We retrospectively analyzed the clinical data on 111 cases of sexual dysfunction (including disorders in erection, ejaculation or libido) treated in the Zhengzhou University First Hospital from June to September 2023. According to the patients' complaints of low libido or accompanied symptoms, we divided them into a normal libido group (n = 68) and a low libido (n = 43), obtained their scores on IIEF-5, Premature Ejaculation Diagnostic Tool (PEDT), 13-Item Self-Rating Libido Scale for Males (SRLS-M), Patients' Health Questionnaire-9 (PHQ-9) and General Anxiety Disorder-7 (GAD-7), examined the levels of the sexual hormones FSH, LH, PRL, T, free testosterone (fT), E2,?insulin-like growth factor 1 (IGF-1) and growth hormone (GH), compared the basic parameters between the two groups, and analyzed their correlation with the libido values.
J Anim Sci
July 2025
Agriculture and Agri-Food Canada, Sherbrooke Research and Development Centre, 2000 College, Sherbrooke, QC, Canada J1M 0C8.
The aim of this project was to determine the impact of either increasing standardized ileal digestible (SID) Lys intake by 40% in gilts from days 85 to 111 of gestation, or combining that treatment with an increase in prolactin concentrations during lactation, on sow and piglet performances. On day 85 of gestation gilts were divided in three groups: 1) fed SID Lys at estimated NRC requirement (CTL, control, n =23) until day 111 of gestation, 2) fed SID Lys at 40% above requirement via additional soybean meal (LYS, n = 22) until day 111 of gestation, or 3) fed SID Lys at 40% above requirement via additional soybean meal (LYSDOMP, n = 21) until day 111 of gestation and receiving domperidone throughout lactation. Experimental diets were isoenergetic.
View Article and Find Full Text PDFFront Nutr
June 2025
Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
Background: Insulin-like Growth Factor I (IGF-I) and Vitamin D are crucial for growth and metabolism, with their levels declining with age. However, their mutual interactions and contributions to body composition remain unclear.
Objectives: To examine the relationships between IGF-I, Vitamin D, and body composition in geriatric outpatients, and to test the mediational role of IGF-I in the association between Vitamin D and Fat-Free Mass (FFM).
Sci Rep
July 2025
Department of Preventive Dentistry, Guangdong Engineering Research Center of Oral Restoration and Reconstruction, Guangzhou Key Laboratory of Basic and Applied Research of Oral Regenerative Medicine, Affiliated Stomatology Hospital of Guangzhou Medical University, Guangzhou, China.
Insulin-like growth factor-binding protein 5 (IGFBP5) is associated with nonalcoholic fatty liver disease (NAFLD). IGFBP5 has a higher binding affinity to IGF1 and modulates its effects in serum. However, the effect of exercise on its expression remains unclear.
View Article and Find Full Text PDFPLoS One
June 2025
Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran.
This study investigates the potential of delivering ghrelin via chitosan-alginate (Cs-Al) nanocapsules to enhance growth performance, immune function, and stress biomarker parameters in common carp fry (Cyprinus carpio). Characterization of the nanoparticles revealed an average size of 130 nm for Cs-Al particles and 150 nm for A-ghrelin-loaded nanoparticles, with polydispersity indices (PDI) of 0.3 and 0.
View Article and Find Full Text PDF